Modern urology research requires predictive, human-relevant bladder and urinary tract models that are robust for screening and closely aligned with patient biology. CELLnTEC enables advanced in vitro bladder models using HBLAK long-term cells, progenitor-targeted media, and Higher Certified formulations to support clinically translatable research and improved decision-making.
Our robust 2D monolayers, 3D organoids, and urine-tolerant bladder models support cancer, UTI, barrier, and translational urology studies. These physiologically relevant models replicate urothelial differentiation, barrier integrity, and functional responses under exposure to urine, improving predictive drug screening and disease modeling accuracy.
Bladder infections, inflammation, incontinence, and bladder cancer affect millions worldwide. CELLnTEC supports bladder disease research and urinary tract research by enabling in vitro urothelial models that replicate human bladder epithelial biology, advancing diagnostics, therapeutic development, and mechanistic insight.
Our toolkit includes HBLAK long-term bladder cells, precision urothelial cell culture media, and optimized systems for bladder biopsy isolation, expansion, and differentiation. These platforms support 2D monolayers, 3D bladder organoid models, and co-culture systems for bladder microenvironment modelling and reproducible translational workflows.
For bladder cancer research, our models enable controlled epithelial growth dynamics, differentiation profiling, and anti-cancer response testing. These screening-ready platforms support high-throughput screening, biomarker discovery, and translational oncology strategies aligned with patient-derived biology.
CELLnTEC provides infection-ready models for urinary tract infection (UTI) research, supporting host–pathogen interactions, antimicrobial testing, and inflammation pathway analysis. Researchers can investigate urothelial barrier function, barrier integrity, and mechanosensory signalling under clinically relevant conditions.
Our urine-tolerant in vitro bladder models allow controlled exposure to urine, better reflecting in vivo urinary tract environments. These systems enhance predictive modelling of inflammation responses, therapy performance, and urothelial barrier integrity, strengthening translational relevance and drug development reliability.
CELLnTEC supports bridging discovery research with patient-derived models through standardized workflows and screening-ready platforms. Our systems align with ATMP-oriented workflows, enabling consistency, traceability, and manufacturing-compatible processes for advanced therapy medicinal product development and translational medicine.
High-yield expansion of primary urothelial cells from bladder biopsies.
Harmonised culture conditions across multiple epithelial tissues to support multi-organ studies.
Xeno-free, chemically defined formulations compatible with regulatory expectations.
Development of urine-tolerant urothelial organoids and mini-bladder models.
Evaluation of urothelial barrier integrity, permeability, and tight junction regulation.
Disease modelling, biomarker discovery, and stability testing using HBLAK.
Regenerative urology and tissue engineering for urinary tract reconstruction.
1
HBLAK long-term cells for models that capture normal urothelium and long-term expansion needs in one platform.
3
Cultivate urine-tolerant 3D microtissues for studying infection, inflammation, and urine composition effects under physiologically relevant conditions.
2
Seamless progression from 2D expansion to 3D differentiation in airlift culture supporting stratified, barrier-forming urothelium.
4
Detailed bladder isolation and culture protocols are described in publications for reproducible and scalable models.
Primary epithelial cells growing in CnT-NX-EX display a highly proliferative phenotype. For differentiation experiments, it is recommended to switch to the CnT-PR-D or CnT-PR-3D differentiation media.
